申请人:Euroceltique, S.A.
公开号:US04925847A1
公开(公告)日:1990-05-15
A 6-thioxanthine of general formula I or a pharmaceutically acceptable salt thereof ##STR1## wherein R.sub.3 is a C.sub.2 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group and R.sub.8 is a C.sub.1 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group provided that when R.sub.3 is an ethyl, n-propyl or n-butyl group, R.sub.8 is a C.sub.3 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group. These 3,8-disubstituted-6-thioxanthines have enhanced bronchodilator activity.
通式I的6-硫代黄嘌呤或其药学上可接受的盐,其中R.sub.3是C.sub.2到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基,R.sub.8是C.sub.1到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基,但当R.sub.3为乙基,正丙基或正丁基时,R.sub.8是C.sub.3到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基。这些3,8-二取代-6-硫代黄嘌呤具有增强的支气管扩张剂活性。